Isturisa

Osilodrostat, the active ingredient in Isturisa, is a steroidogenesis inhibitor presented as a tablet for oral use. It reduces cortisol synthesis and is indicated for the treatment of Cushing's disease and Cushing's syndrome in patients with endogenous hypercortisolism. The medication is approved for use within the European Union and is prescribed by endocrinologists experienced in managing adrenal disorders.

GNH USA supplies Isturisa as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. All batches are manufactured under GMP standards and undergo rigorous quality testing before distribution.

Isturisa (osilodrostat) is used to manage disorders of excess cortisol production. - Cushing's disease: lowers cortisol levels in patients with pituitary ACTH‑secreting tumors. - Cushing's syndrome: reduces cortisol in patients with ectopic ACTH production or adrenal causes. - Endogenous hypercortisolism: helps control cortisol excess regardless of source.

Common Side Effects: - Nausea - Fatigue - Headache - Dizziness

Serious or Rare Side Effects: - Adrenal crisis - Severe hypokalemia - Hepatic injury

Before initiating therapy, consider the following precautions: - Monitor cortisol levels: adjust dose based on biochemical response. - Assess for adrenal insufficiency: watch for signs of under‑replacement. - Check electrolyte balance: especially potassium and sodium. - Use caution in hepatic impairment: dose may need adjustment. - Avoid use in pregnancy: safety is unknown; only if benefit outweighs risk. - Store at below 25°C: keep in the original pack, protect from moisture.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole) may increase osilodrostat exposure. - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine) may reduce osilodrostat effectiveness.

Moderate Interactions (Monitor Closely): - Moderate CYP3A4 inhibitors (e.g., erythromycin) can modestly raise drug levels. - CYP2C19 inhibitors (e.g., fluoxetine) may increase exposure. - QT‑prolonging agents (e.g., macrolide antibiotics) may heighten cardiac risk.